Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
+44 1223 790975
ISSN: 2155-9899
+44 1223 790975
Pier Luigi Meroni
Istituto G. Pini, Piazza C. Ferrari,
1 – 20122 Milano
Italy
Review Article
Reactivity against the Five Domains of β2 Glycoprotein I: A Focus on Systemic Lupus Erythematosus
Author(s): Cecilia Beatrice Chighizola, Maria Orietta Borghi, Claudia Grossi, Francesca Pregnolato, Maria Gerosa and Pier Luigi MeroniCecilia Beatrice Chighizola, Maria Orietta Borghi, Claudia Grossi, Francesca Pregnolato, Maria Gerosa and Pier Luigi Meroni
Beta-2 glycoprotein I (β2GPI) is the main antigenic target for antiphospholipid antibodies (aPL), the serological markers of antiphospholipid syndrome (APS), a systemic autoimmune disease characterized by vascular thrombosis and/or pregnancy morbidity. aPL are detected in 20 to 50% of patients with systemic lupus erythematosus (SLE), representing a poor prognostic factor. Indeed, thrombotic events heralds high morbidity and mortality, being regarded as the strongest predictors of death in the first five years after SLE onset. It would be thus very important to identify a reliable laboratory tool such as anti-domain antibodies to better risk-stratify lupus patients according to the aPL profile, in order to tailor treatment strategies. Domain I (DI) of β2GPI has lately been identified as the main epitope targeted by antibodies reacting against β.. View More»
DOI:
10.4172/2155-9899.1000206